ERK/p90(RSK)/14-3-3 Signalling Has an Impact on Expression of PEA3 Ets Transcription Factors Via the Transcriptional Repressor Capicúa
Overview
Authors
Affiliations
Compounds that inhibit signalling upstream of ERK (extracellular-signal-regulated kinase) are promising anticancer therapies, motivating research to define how this pathway promotes cancers. In the present study, we show that human capicúa represses mRNA expression for PEA3 (polyoma enhancer activator 3) Ets transcription factors ETV1, ETV4 and ETV5 (ETV is Ets translocation variant), and this repression is relieved by multisite controls of capicúa by ERK, p90(RSK) (p90 ribosomal S6 kinase) and 14-3-3 proteins. Specifically, 14-3-3 binds to p90(RSK)-phosphorylated Ser¹⁷³ of capicúa thereby modulating DNA binding to its HMG (high-mobility group) box, whereas ERK phosphorylations prevent binding of a C-terminal NLS (nuclear localization sequence) to importin α4 (KPNA3). ETV1, ETV4 and ETV5 mRNA levels in melanoma cells are elevated by siRNA (small interfering RNA) knockdown of capicúa, and decreased by inhibiting ERK and/or expressing a form of capicúa that cannot bind to 14-3-3 proteins. Capicúa knockdown also enhances cell migration. The findings of the present study give further mechanistic insights into why ETV1 is highly expressed in certain cancers, indicate that loss of capicúa can desensitize cells to the effects of ERK pathway inhibitors, and highlight interconnections among growth factor signalling, spinocerebellar ataxias and cancers.
It's all downstream from here: RTK/Raf/MEK/ERK pathway resistance mechanisms in glioblastoma.
Yakubov R, Kaloti R, Persaud P, McCracken A, Zadeh G, Bunda S J Neurooncol. 2025; .
PMID: 39821893 DOI: 10.1007/s11060-024-04930-w.
The Capicua C1 Domain Is Required for Full Activity of the CIC::DUX4 Fusion Oncoprotein.
Luck C, Jacobs K, Okimoto R Cancer Res Commun. 2024; 4(12):3099-3113.
PMID: 39530749 PMC: 11626509. DOI: 10.1158/2767-9764.CRC-24-0348.
The C1 Domain is Required for Full Activity of the CIC::DUX4 Fusion Oncoprotein.
Luck C, Jacobs K, Okimoto R bioRxiv. 2024; .
PMID: 38895482 PMC: 11185703. DOI: 10.1101/2024.06.06.597815.
Park J, Lee J, Hur Y, Kim C, Kim H, Um D Proc Natl Acad Sci U S A. 2024; 121(24):e2322009121.
PMID: 38843187 PMC: 11181037. DOI: 10.1073/pnas.2322009121.
Therapeutic targeting of p90 ribosomal S6 kinase.
Wright E, Lannigan D Front Cell Dev Biol. 2024; 11:1297292.
PMID: 38169775 PMC: 10758423. DOI: 10.3389/fcell.2023.1297292.